Bromide

Bromide

SCHEMBL1872736

C[N@+]1(CCOc2ccccc2)CC[C@H](OC(=O)C(O)(c2ccccc2)c2ccccc2)CC1.[Br-]

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRM3 known ✓ P20309 14/20 0.62
CHRM2 known ✓ P08172 13/20 0.59
CHRM1 known ✓ P11229 4/20 0.59
RAB9A P51151 1/20 0.58
SLC22A1 O15245 1/20 0.57
KCNH2 Q12809 3/20 0.56
LMNA P02545 2/20 0.56
CYP2D6 P10635 2/20 0.56
HRH1 P35367 2/20 0.56
CYP2C19 P33261 1/20 0.55
SLC6A4 P31645 1/20 0.55
OPRK1 P41145 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1872734 1.00 CHRM3 (0.62) CHRM3CHRM2CHRM1RAB9ASLC22A1
Bromide SCHEMBL1876891 0.94 CHRM3 (0.63) CHRM3CHRM2CHRM1RAB9ASLC22A1
Bromide SCHEMBL1879232 0.87 RAB9A (0.75) CHRM3CHRM2CHRM1RAB9ASLC22A1
Bromide SCHEMBL1874561 0.87 RAB9A (0.75) CHRM3CHRM2CHRM1RAB9ASLC22A1
Bromide SCHEMBL1874562 0.87 RAB9A (0.75) CHRM3CHRM2CHRM1RAB9ASLC22A1
Bromide SCHEMBL1087613 0.86 CHRM3 (0.66) CHRM3CHRM2CHRM1KCNH2CYP2D6
Bromide SCHEMBL1875236 0.86 CHRM3 (0.62) CHRM3CHRM2CHRM1KCNH2HRH1
Bromide SCHEMBL1875238 0.86 CHRM3 (0.62) CHRM3CHRM2CHRM1KCNH2HRH1
SCHEMBL3312449 0.84 CHRM3 (0.62) CHRM3CHRM2CHRM1KCNH2HRH1
SCHEMBL1088393 0.81 CHRM2 (0.55) CHRM3CHRM2CHRM1RAB9ASLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947730-B2 Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic M3 receptor NOVARTIS AG (CH) 2011-05-24 US disclosed
US-20060287362-A1 Organic compounds NOVARTIS AG (CH) 2006-12-21 US disclosed
EP-1638940-A2 PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS FOR THE MUSCARINIC M3 RECEPTOR Novartis AG (CH) 2006-03-29 EP disclosed
WO-2005000815-A2 PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS FOR THE MUSCARINIC M3 RECEPTOR NOVARTIS AG (CH) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287362-A1 Organic compounds CHRM2, CHRM3, CHRM1 CHRM3 2/4885CHRM2 1/4885CHRM1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.